- Home
- GIS vs ARGX Comparison
GIS vs ARGX Comparison
Compare GIS & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIS
- ARGX
- Stock Information
- Founded
- GIS 1866
- ARGX 2008
- Country
- GIS United States
- ARGX Netherlands
- Employees
- GIS N/A
- ARGX N/A
- Industry
- GIS Packaged Foods
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GIS Consumer Staples
- ARGX Health Care
- Exchange
- GIS Nasdaq
- ARGX Nasdaq
- Market Cap
- GIS 34.9B
- ARGX 37.3B
- IPO Year
- GIS N/A
- ARGX 2017
- Fundamental
- Price
- GIS $60.24
- ARGX $650.39
- Analyst Decision
- GIS Hold
- ARGX Strong Buy
- Analyst Count
- GIS 16
- ARGX 20
- Target Price
- GIS $70.07
- ARGX $653.11
- AVG Volume (30 Days)
- GIS 3.8M
- ARGX 249.0K
- Earning Date
- GIS 12-18-2024
- ARGX 02-27-2025
- Dividend Yield
- GIS 4.03%
- ARGX N/A
- EPS Growth
- GIS 11.96
- ARGX N/A
- EPS
- GIS 4.60
- ARGX N/A
- Revenue
- GIS $19,901,300,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- GIS $1.39
- ARGX $70.98
- Revenue Next Year
- GIS $0.79
- ARGX $51.22
- P/E Ratio
- GIS $12.96
- ARGX N/A
- Revenue Growth
- GIS N/A
- ARGX 85.56
- 52 Week Low
- GIS $57.94
- ARGX $349.86
- 52 Week High
- GIS $75.90
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- GIS 39.11
- ARGX 57.29
- Support Level
- GIS $59.05
- ARGX $635.85
- Resistance Level
- GIS $61.00
- ARGX $655.52
- Average True Range (ATR)
- GIS 1.17
- ARGX 15.67
- MACD
- GIS 0.06
- ARGX -1.53
- Stochastic Oscillator
- GIS 30.35
- ARGX 54.50
About GIS General Mills Inc.
General Mills is a global packaged food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2024, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.